NASDAQ:BMRN

Biomarin Pharmaceutical Stock Insider Trading

etoro logo Buy BMRN
*Your capital is at risk
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026

BioMarin Pharmaceutical Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 6.10. In total, the insiders bought 820.92K and sold 149.11K BMRN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
6.10
Buy 820.92K shares
Sell 149.11K shares
70% Buy Activity
Moderate Negative Correlation
Buy Signal Low Confidence
Mar 16, 2026

Analysis Breakdown:

  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Dec 31, 2025
Buy
Common Stock
J-Other
Meier Richard A
Director 0
Value: $0
Dec 31, 2025
Buy
Common Stock
J-Other
Hubbard Cristin
Officer
Officer 0
Value: $0
Dec 31, 2025
Buy
Common Stock
J-Other
Guyer Charles Greg
Officer
Officer 0
Value: $0
Dec 31, 2025
Buy
Common Stock
J-Other
Friberg Gregory R
Officer
Officer 0
Value: $0
Dec 31, 2025
Buy
Common Stock
J-Other
Davis George Eric
Officer
Officer 0
Value: $0
Dec 01, 2025
Sell
Common Stock
F-InKind
Hardy Alexander
Chief Executive Officer
CEO / President 16 570
Value: $911.8K
Sep 30, 2025
Sell
Common Stock
F-InKind
Friberg Gregory R
EVP, Chief R&d Officer
Officer 3 304
Value: $178.9K
Sep 30, 2025
Sell
Common Stock
F-InKind
Friberg Gregory R
EVP, Chief R&d Officer
Officer 3 304
Value: $178.9K
Aug 01, 2025
Buy
Common Stock
A-Award
Clark Ian T
Director
Director 7 000
Value: $407.0K
Aug 01, 2025
Buy
Common Stock
J-Other
Clark Ian T
Director 0
Value: $0
Aug 01, 2025
Buy
Common Stock
J-Other
Clark Ian T
Director 0
Value: $0
Aug 01, 2025
Buy
Common Stock
A-Award
Clark Ian T
Director
Director 7 000
Value: $407.0K
May 20, 2025
Sell
Common Stock
F-InKind
Hubbard Cristin
EVP, Chief Commercial Officer
Officer 2 155
Value: $129.1K
May 20, 2025
Buy
Common Stock
A-Award
Walbert Timothy P
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Meier Richard A
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Hombach Robert J.
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Ho Maykin
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Enyedy Mark J
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Dere Willard H
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Countouriotis Athena
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Bodem Barbara W.
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Anderson Elizabeth M
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Anderson Elizabeth M
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Bodem Barbara W.
Director
Director 6 650
Value: $398.5K
May 20, 2025
Buy
Common Stock
A-Award
Countouriotis Athena
Director
Director 6 650
Value: $398.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT BIOMARIN PHARMACEUTICAL INC.
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...
GOLDEN STAR
Ticker Change Signal Date
FOX
$50.81
2.22% Jul 27
UNFI
$49.05
3.63% Jul 27
BIIB
$202.19
0.376% Jul 24
TSCO
$30.32
1.48% Jul 23
S
SW
$43.71
5.17% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE